JPWO2021226440A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021226440A5 JPWO2021226440A5 JP2022566686A JP2022566686A JPWO2021226440A5 JP WO2021226440 A5 JPWO2021226440 A5 JP WO2021226440A5 JP 2022566686 A JP2022566686 A JP 2022566686A JP 2022566686 A JP2022566686 A JP 2022566686A JP WO2021226440 A5 JPWO2021226440 A5 JP WO2021226440A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyldiyl
- immunoconjugate
- espep
- alkyl
- och
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 61
- 229940127121 immunoconjugate Drugs 0.000 claims 48
- -1 alkyldiyl Chemical group 0.000 claims 37
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 239000000758 substrate Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000004452 carbocyclyl group Chemical group 0.000 claims 7
- 230000003308 immunostimulating effect Effects 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 6
- 125000006693 (C2-C9) heterocyclyl group Chemical group 0.000 claims 5
- 102000016387 Pancreatic elastase Human genes 0.000 claims 5
- 108010067372 Pancreatic elastase Proteins 0.000 claims 5
- 239000011230 binding agent Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 5
- 125000006519 CCH3 Chemical group 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims 3
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 3
- 229940097043 glucuronic acid Drugs 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 2
- 230000021615 conjugation Effects 0.000 claims 2
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 claims 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- GJMNLCSOIHOLQZ-FXQIFTODSA-N Ala-Ala-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)N)C(O)=O GJMNLCSOIHOLQZ-FXQIFTODSA-N 0.000 claims 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 claims 1
- 102100037435 Antiviral innate immune response receptor RIG-I Human genes 0.000 claims 1
- 101710127675 Antiviral innate immune response receptor RIG-I Proteins 0.000 claims 1
- VHQSGALUSWIYOD-QXEWZRGKSA-N Asn-Pro-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O VHQSGALUSWIYOD-QXEWZRGKSA-N 0.000 claims 1
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 1
- 101001125026 Homo sapiens Nucleotide-binding oligomerization domain-containing protein 2 Proteins 0.000 claims 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 1
- 102100029441 Nucleotide-binding oligomerization domain-containing protein 2 Human genes 0.000 claims 1
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 1
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 229940044665 STING agonist Drugs 0.000 claims 1
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102000002689 Toll-like receptor Human genes 0.000 claims 1
- 108020000411 Toll-like receptor Proteins 0.000 claims 1
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006593 Urologic Neoplasms Diseases 0.000 claims 1
- 108010087049 alanyl-alanyl-prolyl-valine Proteins 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 229950002916 avelumab Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229950009791 durvalumab Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 229950000518 labetuzumab Drugs 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 102000007863 pattern recognition receptors Human genes 0.000 claims 1
- 108010089193 pattern recognition receptors Proteins 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229950001460 sacituzumab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063022069P | 2020-05-08 | 2020-05-08 | |
| US63/022,069 | 2020-05-08 | ||
| PCT/US2021/031264 WO2021226440A1 (en) | 2020-05-08 | 2021-05-07 | Elastase-substrate, peptide linker immunoconjugates, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524271A JP2023524271A (ja) | 2023-06-09 |
| JP2023524271A5 JP2023524271A5 (https=) | 2024-04-24 |
| JPWO2021226440A5 true JPWO2021226440A5 (https=) | 2024-04-24 |
Family
ID=76181275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566686A Withdrawn JP2023524271A (ja) | 2020-05-08 | 2021-05-07 | エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230293716A1 (https=) |
| EP (1) | EP4146282A1 (https=) |
| JP (1) | JP2023524271A (https=) |
| CN (1) | CN115996756A (https=) |
| CA (1) | CA3176626A1 (https=) |
| WO (1) | WO2021226440A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102726248B1 (ko) | 2016-07-07 | 2024-11-05 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| JP7695885B2 (ja) | 2019-02-12 | 2025-06-19 | アンブルックス，インコーポレイテッド | 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN116234586A (zh) * | 2020-08-13 | 2023-06-06 | 博尔特生物治疗药物有限公司 | 吡唑并氮呯免疫缀合物及其用途 |
| WO2022125908A1 (en) * | 2020-12-11 | 2022-06-16 | Bolt Biotherapeutics, Inc. | Anti-pd-l1 immunoconjugates, and uses thereof |
| CN116635084A (zh) * | 2020-12-11 | 2023-08-22 | 博尔特生物治疗药物有限公司 | 抗cea免疫缀合物和其用途 |
| US20240091370A1 (en) * | 2020-12-11 | 2024-03-21 | Bolt Biotherapeutics, Inc. | Anti-her2 immunoconjugates, and uses thereof |
| JP2023552791A (ja) * | 2020-12-11 | 2023-12-19 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗ｈｅｒ２免疫複合体、及びその使用 |
| US20220195066A1 (en) * | 2020-12-11 | 2022-06-23 | Bolt Biotherapeutics, Inc. | Anti-cea immunoconjugates, and uses thereof |
| CN118475372A (zh) * | 2021-10-29 | 2024-08-09 | 博尔特生物治疗药物有限公司 | 具有半胱氨酸突变抗体的tlr激动剂免疫缀合物及其用途 |
| WO2023154318A1 (en) * | 2022-02-09 | 2023-08-17 | Bolt Biotherapeutics, Inc. | Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof |
| TW202339806A (zh) * | 2022-02-09 | 2023-10-16 | 美商博特生物治療公司 | ８—磺醯基—苯并氮呯免疫結合物及其用途 |
| CN118843480A (zh) * | 2022-02-09 | 2024-10-25 | 博尔特生物治疗药物有限公司 | 高分子负载的8-磺酰基-苯并氮杂䓬化合物及其用途 |
| WO2024174863A1 (zh) * | 2023-02-22 | 2024-08-29 | 深圳众格生物科技有限公司 | Sting激动剂及其制备方法和医药用途 |
| GB202407865D0 (en) * | 2024-06-03 | 2024-07-17 | Elasmogen Ltd | Self immolative compounds |
| WO2026078593A1 (en) | 2024-10-08 | 2026-04-16 | Sun Pharma Advanced Research Company Limited | Sting agonists and antibody drug conjugates thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US723288A (en) | 1901-10-26 | 1903-03-24 | Harry South Lewis | Cipher-key for cryptographic codes. |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| PT1308456E (pt) | 1998-05-06 | 2007-12-03 | Genentech Inc | Purificação de anticorpos por cromatografia de permuta iónica |
| CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| CA2399940A1 (en) | 2000-04-13 | 2001-10-25 | The Rockefeller University | Enhancement of antibody-mediated immune responses |
| EP1238678A1 (en) | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| WO2005086875A2 (en) | 2004-03-11 | 2005-09-22 | City Of Hope | A humanized anti-cea t84.66 antibody and uses thereof |
| KR101270829B1 (ko) | 2004-09-23 | 2013-06-07 | 제넨테크, 인크. | 시스테인 유전자조작 항체 및 접합체 |
| WO2006073921A2 (en) | 2004-12-30 | 2006-07-13 | The Rockefeller University | Compositions and methods for enhanced dendritic cell maturation and function |
| US20080286819A1 (en) | 2005-11-07 | 2008-11-20 | Ravetch Jeffrey V | Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof |
| LT1976880T (lt) | 2005-12-21 | 2016-10-10 | Amgen Research (Munich) Gmbh | Farmacinės kompozicijos, pasižyminčios atsparumu tirpiam cea |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20080131428A1 (en) | 2006-02-24 | 2008-06-05 | Arius Research, Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| MX2010003718A (es) | 2007-10-19 | 2010-04-21 | Genentech Inc | Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo. |
| EP3912643B8 (en) | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| ES2978177T3 (es) | 2009-12-02 | 2024-09-06 | Immunomedics Inc | Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| MX369106B (es) | 2010-05-17 | 2019-10-29 | Chiome Bioscience Inc | Anticuerpo anti trop-2 humano que tiene actividad anti-tumoral in vivo. |
| JPWO2011155579A1 (ja) | 2010-06-10 | 2013-08-15 | 北海道公立大学法人 札幌医科大学 | 抗Ｔｒｏｐ−２抗体 |
| JP5889912B2 (ja) | 2010-11-17 | 2016-03-22 | ジェネンテック， インコーポレイテッド | アラニニルメイタンシノール抗体コンジュゲート |
| RS56793B1 (sr) | 2011-03-02 | 2018-04-30 | Roche Glycart Ag | Cea antitela |
| RU2595400C2 (ru) | 2011-08-04 | 2016-08-27 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| PT2740794T (pt) | 2011-08-04 | 2018-06-14 | Toray Industries | Composição farmacêutica para o tratamento e/ou profilaxia de cancro |
| US9181348B2 (en) | 2011-08-04 | 2015-11-10 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PT2740793T (pt) | 2011-08-04 | 2018-02-23 | Toray Industries | Composição de fármacos para o tratamento e/ou a prevenção de cancro |
| AU2012335205A1 (en) | 2011-11-11 | 2014-05-29 | Rinat Neuroscience Corp. | Antibodies specific for Trop-2 and their uses |
| US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
| US9260513B2 (en) | 2012-02-21 | 2016-02-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| HUE044611T2 (hu) | 2012-02-21 | 2019-11-28 | Toray Industries | Gyógyászati készítmény rák kezelésére |
| BR112014021103A2 (pt) | 2012-02-21 | 2019-10-15 | Toray Industries, Inc | Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo |
| PT2818483T (pt) | 2012-02-21 | 2017-10-09 | Toray Industries | Composição medicinal para tratamento e/ou prevenção de cancro |
| RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| US9382329B2 (en) | 2012-08-14 | 2016-07-05 | Ibc Pharmaceuticals, Inc. | Disease therapy by inducing immune response to Trop-2 expressing cells |
| HUE033369T2 (en) | 2012-11-20 | 2017-11-28 | Sanofi Sa | Anti-ceacam5 antibodies and uses thereof |
| ES2704909T3 (es) | 2013-08-09 | 2019-03-20 | Toray Industries | Composición farmacéutica para el tratamiento y/o la prevención del cáncer |
| LT3424955T (lt) | 2013-12-25 | 2025-06-25 | Daiichi Sankyo Company, Limited | Anti-trop2 antikūno ir vaisto konjugato gamybos būdas |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| TW201623265A (zh) | 2014-05-09 | 2016-07-01 | 奇尼塔公司 | 抗病毒化合物、醫藥組合物及其使用方法 |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| WO2016172427A1 (en) | 2015-04-22 | 2016-10-27 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| WO2017156152A1 (en) | 2016-03-08 | 2017-09-14 | Bioxcel Corporation | Immunomodulation therapies for cancer |
| KR20240005247A (ko) | 2016-10-28 | 2024-01-11 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CN111194214A (zh) * | 2017-10-05 | 2020-05-22 | 葛兰素史密斯克莱知识产权发展有限公司 | 施用sting激动剂的方法 |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| WO2019222676A1 (en) * | 2018-05-17 | 2019-11-21 | Bolt Biotherapeutics, Inc. | Immunoconjugates |
| CN113543808A (zh) | 2019-01-04 | 2021-10-22 | 特瑞奥制药公司 | 多特异性蛋白质分子及其用途 |
| AU2020291014B2 (en) * | 2019-06-13 | 2025-06-05 | Bolt Biotherapeutics, Inc. | Aminobenzazepine compounds, immunoconjugates, and uses thereof |
| CA3148694A1 (en) * | 2019-09-03 | 2021-03-11 | Romas Kudirka | Aminoquinoline compounds, immunoconjugates, and uses thereof |
| JP2022549510A (ja) * | 2019-09-30 | 2022-11-25 | ボルト バイオセラピューティクス、インコーポレーテッド | アミド結合したアミノベンズアゼピン免疫複合体、及びその使用 |
| CA3155077A1 (en) * | 2019-10-25 | 2021-04-29 | Romas Kudirka | Thienoazepine immunoconjugates, and uses thereof |
-
2021
- 2021-05-07 CN CN202180046241.8A patent/CN115996756A/zh active Pending
- 2021-05-07 CA CA3176626A patent/CA3176626A1/en active Pending
- 2021-05-07 WO PCT/US2021/031264 patent/WO2021226440A1/en not_active Ceased
- 2021-05-07 US US17/923,541 patent/US20230293716A1/en active Pending
- 2021-05-07 EP EP21728751.5A patent/EP4146282A1/en not_active Withdrawn
- 2021-05-07 JP JP2022566686A patent/JP2023524271A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021226440A5 (https=) | ||
| JP6704900B2 (ja) | ポリオキサゾリン抗体薬物複合体 | |
| JP6929292B2 (ja) | 新規なクリプトフィシン化合物およびコンジュゲート、これらの製造およびこれらの治療用途 | |
| NO171684B (no) | Analogifremgangsmaate til fremstilling av terapeutisk aktiv polyetylenglykolkarbaminater | |
| WO2020145228A1 (ja) | 配位子及びＣＥＡＣＡＭ５抗体Ｆａｂフラグメントからなる複合体 | |
| JP2026501617A (ja) | Ｎ－ハロアルキル置換カンプトテシン誘導体の抗体複合薬物 | |
| JPWO2020252294A5 (https=) | ||
| JPWO2021067242A5 (https=) | ||
| JP2023537248A (ja) | ポリエチレングリコール複合薬相乗剤、その調製方法およびその使用 | |
| CN120826407A (zh) | 包含曲贝替定和芦比替定衍生物的抗体药物偶联物 | |
| JPWO2022272039A5 (https=) | ||
| JP2026501616A (ja) | Ｎ－メチレンアミドリンカーを含有する抗体－薬物複合体 | |
| AU2017340314B2 (en) | Cysteine modified antibody-drug conjugate and preparation method thereof | |
| JPWO2021081407A5 (https=) | ||
| FR2670787A1 (fr) | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. | |
| JP2023505509A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| JPWO2022246576A5 (https=) | ||
| JP2010516633A (ja) | 抗癌活性を有するテトラサイクリン・アントラキノン系化合物 | |
| WO2025047983A1 (ja) | がん特異的酵素活性を標的とした新規プロドラッグ型抗がん剤 | |
| JP2023537247A (ja) | ポリエチレングリコール複合薬、ならびにその調製方法およびその使用 | |
| JPWO2021046112A5 (https=) | ||
| JPWO2022204536A5 (https=) | ||
| JP6928354B2 (ja) | クインスタチン化合物 | |
| JPWO2021081402A5 (https=) | ||
| JPWO2020089687A5 (https=) |